138 results
P
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy
I/C
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy
O
Excess weight loss, Type 2 diabetes mellitus resolution, Postoperative complication and reoperation rates, Dyslipidemia, Hypertension, Gastroesophageal reflux disease
P
monolithic translucent Y-TZP ceramics
I/C
hydrothermal aging, aged Y-TZP ceramics
O
translucency parameter (TP), L*
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
FTSF, V-Y closure, perforator flap, non-perforator flap
I/C
separately combined full-thickness skin graft (FTSG), FTSG method based on V-Y closure, perforator flap, non-perforator flap
O
adapted FRFF size, postoperative complications
P
morbid obesity patients
I/C
laparoscopic sleeve gastrectomy (LSG), Roux-en-Y laparoscopic gastric bypass (RYLGB)
O
weight loss, resolution of comorbidities, postoperative complications, operative time, hospital stay, and improvement in quality of life
P
Orthodontic-surgical treatment patients
I/C
Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments
O
Oral health-related quality of life
P
patients with advanced cancer
I/C
receiving immune checkpoint inhibitors (ICIs), sarcopenia vs. no sarcopenia
O
response rate, 1-y progression-free survival (PFS) rate, 1-y overall survival (OS) rate, hazard ratios (HRs) of PFS and OS
P
patients with localized infections
I/C
antibiotics formulated at concentrations between 0 and 6% w/w into bone cements, gentamycin-infused bone cement mixtures
O
eradication or delay of infection onset
P
Y-TZP ceramics
I/C
low-temperature degradation (LTD), steam autoclave aging
O
surface roughness